Danielle N. Krol

Oncology

900 23rd St NW
Washington, DC 20037

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 21, 2024

The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial Terms.

The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial Terms.

Journal: The oncologist

Published: July 07, 2022

Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].

Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 11, 2022

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 04, 2021

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 04, 2021

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.

Journal: The Lancet. Oncology

Published: June 10, 2021

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 08, 2021

Exploration of baseline patient-reported side effect bother from cancer therapy.

Exploration of baseline patient-reported side effect bother from cancer therapy.

Journal: Clinical trials (London, England)

Published: March 11, 2020

Syndrome of inappropriate antidiuretic hormone in a patient with leptomeningeal carcinomatosis.

Syndrome of inappropriate antidiuretic hormone in a patient with leptomeningeal carcinomatosis.

Journal: Journal of medical case reports

Published: December 02, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026